News and Announcements
4Dx Visits London and Participates in the House of Lords Event
- Published March 17, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
4Dx is pleased to inform you that Chairman and CEO, Andreas Fouras, will be lead speaker at a lunchtime debate at the All Party Parliamentary Engineering Group ‘APPEG’ in the House of Lords, London on Tuesday 21st March. The debate series represents a plank of the APPEG program to enable contact and involvement between parliamentarians and the engineering profession.
KEY TAKEAWAYS:
- Professor the Lord Broers, Co-Chair of the Group, will introduce the debate on exciting advances in medical imaging.
- “We are delighted to have Professor Fouras, Chairman and CEO of medical technology company 4Dx, who founded this life-changing medical technology company, which aims to augment the capabilities of respiratory diagnostics currently available, leveraging information that has until now remained hidden in X-ray images.”
- 4Dx Executive Director, Steve Peuschel, is currently in London with Andreas as part of a global 4Dx roadshow presenting data, from the first 4Dx in-human study, to a wide range of organizations key to the company’s strategy.
In addition, the company delivered presentations in Washington DC to the Cystic Fibrosis Foundation – the U.S. peak body for Cystic Fibrosis research. The 4Dx roadshow now continues in Europe with industry and potential hospital partners, a key focus of the latter half of the trip.
4Dx Limited is an early stage medical technology company based in Melbourne, Australia, established to commercialise four-dimensional lung imaging technology: 4DxV.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
